Allarity Therapeutics Inc. has filed a prospectus supplement on April 11, 2024, to increase the maximum aggregate offering price of its common stock from $1,350,000 to $2,350,000. This amendment is in accordance with the At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC. The company has already sold $1,348,908 worth of common stock within the last 12 months and is now eligible to sell up to an additional $1,015,290. The prospectus supplement is a continuation of the company's previous filings, including the prospectus dated November 29, 2023, and the prospectus supplement dated March 19, 2024. The company's public float was approximately $7,092,593 as of February 28, 2024, based on the closing sales price of $8.56 per share. Allarity Therapeutics cautions that investing in its common stock involves a high degree of risk, as detailed in the 'Risk Factors' section of the March 19, 2024 prospectus supplement.

Allarity Therapeutics Inc. has filed a prospectus supplement on April 11, 2024, to increase the maximum aggregate offering price of its common stock from $1,350,000 to $2,350,000. This amendment is in accordance with the At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC. The company has already sold $1,348,908 worth of common stock within the last 12 months and is now eligible to sell up to an additional $1,015,290. The prospectus supplement is a continuation of the company's previous filings, including the prospectus dated November 29, 2023, and the prospectus supplement dated March 19, 2024. The company's public float was approximately $7,092,593 as of February 28, 2024, based on the closing sales price of $8.56 per share. Allarity Therapeutics cautions that investing in its common stock involves a high degree of risk, as detailed in the 'Risk Factors' section of the March 19, 2024 prospectus supplement.